Get the Stockscreener App
4.03
29.81%
0.93
Precigen Inc stock is traded at $4.03, with a volume of 17.62M.
It is up +29.81% in the last 24 hours and up +5.62% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$3.10
Open:
$4.065
24h Volume:
17.62M
Relative Volume:
3.83
Market Cap:
$1.43B
Revenue:
$6.31M
Net Income/Loss:
$-246.87M
P/E Ratio:
-2.8769
EPS:
-1.4008
Net Cash Flow:
$-75.62M
1W Performance:
+21.20%
1M Performance:
+5.62%
6M Performance:
+14.64%
1Y Performance:
+149.94%
1-Day Range:
$3.73
$4.275
1-Week Range:
$3.04
$4.275
52-Week Range:
$1.11
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.0293 | 1.10B | 6.31M | -246.87M | -75.62M | -1.4008 |
VRTX
Vertex Pharmaceuticals Inc
|
456.62 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.68 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.57 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
696.51 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
149.55 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
Precigen (PGEN) Soars 26% Despite Missed Revenue Estimates - GuruFocus
Precigen (PGEN) Shares Surge on Positive Q1 Outlook Despite Earnings Miss - GuruFocus
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga
PGEN: Analyst Jason N. Butler Raises Price Target to $9 | PGEN S - GuruFocus
Precigen stock gains on Q1 2026 outlook (PGEN:NASDAQ) - Seeking Alpha
PGEN: HC Wainwright & Co. Raises Price Target to $10.00 | PGEN S - GuruFocus
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Precigen stock price target on sales growth - Investing.com
Citizens raises Precigen stock price target on strong PAPZIMEOS sales - Investing.com
Precigen Achieves First Commercial Revenue in 2025 with FDA Approval and Strong US Launch of PAPZIMEOS for RRP - Minichart
Precigen Inc. 2025 Annual Report: Papzimeos Launch, UltraCAR-T & AdenoVerse Platform, Clinical Pipeline, Risks, and Competitive Landscape 33 34 35 38 40 54 - Minichart
Beyond the Balance Sheet: What SWOT Reveals About Precigen Inc (PGEN) - GuruFocus
Q3 2025 Precigen Inc Earnings Call Transcript - GuruFocus
Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion Amidst Challenges - GuruFocus
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen, Inc. (PGEN) reports Q4 loss, lags revenue estimates - MSN
Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad US payer coverage - MSN
Precigen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Precigen (PGEN) Reports Strong Q4 2025 with PAPZIMEOS Launch - GuruFocus
Precigen Q4 Earnings Call Highlights - Yahoo Finance
Precigen, Inc. (PGEN) Posts Fourth Quarter Loss, Misses Revenue Expectations - Bitget
PGEN: PAPZIMEOS launch accelerates revenue growth and adoption, with Q1 2026 revenue set to exceed $18M - TradingView
PGEN: Papzimeos launch accelerates revenue growth, with Q1 2026 sales expected to surpass $18 million - TradingView
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Precigen Inc. beats revenue expectations in Q4 2025 - Investing.com
Precigen (NASDAQ:PGEN) Issues Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Precigen Inc (NASDAQ:PGEN) Stock Surges on Narrower Loss and Commercial Transition After FDA Approval - ChartMill
Precigen 10-K: $9.68M Revenue, $(1.37) EPS on FY net loss - TradingView
Papzimeos launch marks new chapter for Precigen (NASDAQ: PGEN) as pipeline refocuses - Stock Titan
Precigen reports $9.7M revenue, $110.5M operating loss and $429.6M net loss to common in 2025 - TradingView
Precigen Reports Full Year 2025 Financial Results and Business Updates - PR Newswire
Precigen earnings up next: Can gene therapy launch offset losses? By Investing.com - Investing.com Australia
Precigen earnings up next: Can gene therapy launch offset losses? - Investing.com
Precigen Q4 earnings preview - MSN
Precigen (PGEN) Set to Release Q4 Earnings with Modest Expectati - GuruFocus
Precigen Opens Weak with 7.91% Gap Down Amid Market Concerns - Markets Mojo
Precigen Stock Hits Day Low of $3.23 Amid Price Pressure - Markets Mojo
Precigen Insiders Sold US$7.6m Of Shares Suggesting Hesitancy - 富途牛牛
Precigen (NASDAQ:PGEN) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Precigen, Inc. Hits Day Low of $3.27 Amid Price Pressure - Markets Mojo
PRECIGEN (PGEN) CFO receives 40,293 RSUs and converts them into common stock - Stock Titan
Precigen (PGEN) CCO granted 42,110 RSUs that vest immediately and convert to stock - Stock Titan
Precigen (NASDAQ: PGEN) CEO nets 321,100 shares from RSUs - Stock Titan
Precigen (PGEN) COO receives 44,495 RSUs that vest into shares - Stock Titan
PRECIGEN (PGEN) Chief Legal Officer converts 40,443 RSUs into common stock - Stock Titan
Precigen Stock Hits Day Low of $3.94 Amid Price Pressure - Markets Mojo
PGEN Earnings History & Surprises | EPS & Revenue Results | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen (PGEN) insider exercises 143,678 RSUs into common stock - Stock Titan
Director Frank Steven converts 71,839 RSUs into Precigen (PGEN) common stock - Stock Titan
Precigen (PGEN) director converts 71,839 RSUs into common stock, now holding 305,776 shares - Stock Titan
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | Director |
Dec 22 '25 |
Sale |
4.18 |
1,900,036 |
7,942,150 |
341,189 |
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):